Skip to content
Triangle logo TriangleGet started
← Study library

NCT00002670 · CITED IN SOURCE DOCUMENTS

Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery

An NCI or FDA source cites this study. A citation does not establish that it applies to an individual diagnosis.

Phase
PHASE3
Status at capture
COMPLETED
Registry last update
2014-01-24

RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether radiation therapy plus cisplatin is more effective than radiation therapy alone in treating patients with head and neck cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy plus cisplatin with radiation therapy alone in treating patients with head and neck cancer that has been removed during surgery.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

No posted result sections were captured. Registered plans do not establish that a treatment works.

Who could take part
eligibility Criteria
DISEASE CHARACTERISTICS: Biopsy-proven squamous cell carcinoma of one of the following sites: Hypopharynx Larynx Oral cavity Oropharynx At least 1 of the following high-risk factors required: Histologic extracapsular nodal extension Histologic involvement of 2 or more regional lymph nodes Microscopically positive mucosal margins Complete resection of all visible and palpable disease Therapy must begin within 8 weeks of tumor-related surgery Bilateral resections may or may not be performed simultaneously Eligibility window begins with first definitive surgery Neck dissection not required for T4 N0, truly midline supraglottic tumors No tumors of the lip, nasopharynx, or sinuses No synchronous or concurrent head and neck tumors No evidence of distant metastasis Concurrent registration on Fixed Tumor Repository Study allowed PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 60%-100% Hematopoietic: WBC at least 3,500 Platelets at least 100,000 Hepatic: Not specified Renal: Creatinine clearance greater than 50 mL/min Other: No medical contraindication to protocol therapy No second malignancy within 5 years No pregnant or nursing women PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior radiotherapy to head and neck region Surgery: See Disease Characteristics
healthy Volunteers
false
minimum Age
18 Years
sex
ALL
std Ages
  1. ADULT
  2. OLDER_ADULT
Treatment arms and interventions
arm Groups
  1. description
    Radiation therapy - 60 Gy in 6 weeks (2 Gy once a day, 5 x a week)
    intervention Names
    1. Radiation: low-LET cobalt-60 gamma ray therapy
    2. Radiation: low-LET electron therapy
    3. Radiation: low-LET photon therapy
    label
    Radiation therapy
    type
    ACTIVE_COMPARATOR
  2. description
    Radiation therapy - 60 Gy in 6 weeks (2 Gy once a day, 5 x a week) plus Cisplatin-100 mg/m2 i.v. on days 1,22 and 43 with radiation therapy.
    intervention Names
    1. Drug: chemotherapy
    2. Drug: cisplatin
    3. Radiation: low-LET cobalt-60 gamma ray therapy
    4. Radiation: low-LET electron therapy
    5. Radiation: low-LET photon therapy
    label
    Radiation therapy plus cisplatin
    type
    EXPERIMENTAL
interventions
  1. arm Group Labels
    1. Radiation therapy plus cisplatin
    name
    chemotherapy
    type
    DRUG
  2. arm Group Labels
    1. Radiation therapy plus cisplatin
    name
    cisplatin
    type
    DRUG
  3. arm Group Labels
    1. Radiation therapy
    2. Radiation therapy plus cisplatin
    name
    low-LET cobalt-60 gamma ray therapy
    type
    RADIATION
  4. arm Group Labels
    1. Radiation therapy
    2. Radiation therapy plus cisplatin
    name
    low-LET electron therapy
    type
    RADIATION
  5. arm Group Labels
    1. Radiation therapy
    2. Radiation therapy plus cisplatin
    name
    low-LET photon therapy
    type
    RADIATION
Study design
allocation
RANDOMIZED
intervention Model
PARALLEL
masking Info
masking
NONE
primary Purpose
TREATMENT
Enrollment
count
459
type
ACTUAL
Registered outcome plans (not posted results)
Full study description
brief Summary
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether radiation therapy plus cisplatin is more effective than radiation therapy alone in treating patients with head and neck cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of radiation therapy plus cisplatin with radiation therapy alone in treating patients with head and neck cancer that has been removed during surgery.
detailed Description
OBJECTIVES: I. Evaluate locoregional control rates, patterns of first failure, and overall and disease-free survival in patients with advanced squamous cell carcinoma of the head and neck at high risk of locoregional recurrence who are treated postoperatively with concurrent cisplatin and radiotherapy. II. Compare the toxicity of concurrent chemoradiotherapy vs. radiotherapy alone in the postoperative setting. OUTLINE: Randomized study. Arm I: Radiotherapy. Involved-field irradiation using Co60, 1-6 MV photons, or electrons. Arm II: Radiotherapy plus Single-Agent Chemotherapy. Irradiation as in Arm I; plus Cisplatin, CDDP, NSC-119875. PROJECTED ACCRUAL: 438 patients will be entered over approximately 5 years.
Source references
references
  1. citation
    Schumaker L, Nikitakis N, Goloubeva O, Tan M, Taylor R, Cullen KJ. Elevated expression of glutathione S-transferase pi and p53 confers poor prognosis in head and neck cancer patients treated with chemoradiotherapy but not radiotherapy alone. Clin Cancer Res. 2008 Sep 15;14(18):5877-83. doi: 10.1158/1078-0432.CCR-08-0998.
    pmid
    18794100
    type
    BACKGROUND
  2. citation
    Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, Ozsahin EM, Jacobs JR, Jassem J, Ang KK, Lefebvre JL. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501). Head Neck. 2005 Oct;27(10):843-50. doi: 10.1002/hed.20279.
    pmid
    16161069
    type
    BACKGROUND
  3. citation
    Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Lustig R, Ensley JF, Thorstad W, Schultz CJ, Yom SS, Ang KK. Long-term follow-up of the RTOG 9501/intergroup phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys. 2012 Dec 1;84(5):1198-205. doi: 10.1016/j.ijrobp.2012.05.008. Epub 2012 Jun 30.
    pmid
    22749632
    type
    RESULT
  4. citation
    Cooper JS, Pajak TF, Forastiere AA, et al.: Long-term survival results of a phase III intergroup trial (RTOG 95-01) of surgery followed by radiotherapy vs. radiochemotherapy for resectable high risk squamous cell carcinoma of the head and neck. [Abstract] Int J Radiat Oncol Biol Phys 66 (3 Suppl 1): A-25, S14-5, 2006.
    type
    RESULT
  5. citation
    Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK; Radiation Therapy Oncology Group 9501/Intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004 May 6;350(19):1937-44. doi: 10.1056/NEJMoa032646.
    pmid
    15128893
    type
    RESULT
  6. citation
    Cooper JS, Pajak TF, Forastiere AA, et al.: Postoperative concurrent radiochemotherapy in high-risk SCCA of the head and neck: initial report of RTOG 9501/intergroup phase III trial. [Abstract] Proceedings of the American Society of Clinical Oncology 21: A-903, 2002.
    type
    RESULT
  7. citation
    Cooper JS, Pajak TF, Forastiere AA, et al.: Patterns of failure for resected advanced head & neck cancer treated by concurrent chemotherapy and radiation therapy: an analysis of RTOG 9501/intergroup phase III trial. [Abstract] Int J Radiat Oncol Biol Phys 54(2 suppl 1): 2, 2002.
    type
    RESULT
Source notices and limitations
    Discovery and provenance
    1. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-caba98393d63a574bf21
      requested nct id
      NCT00002670
      primary nct id
      NCT00002670
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      31f0b7d3c9f8a622c00428041f6c731a10acf24c59277b3cd1a8fb560d317e44
      payload sha256
      9cefea5896be726b7fd620de756091eeb42cb17348a65fb66e7c6e0369fb31a6
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-caba98393d63a574bf21
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT00002670
      occurrences
      1. context exact
        h node, or positive margins, based on a pooled analysis of the <a href="/clinicaltrials/NCT00002555">EORTC-22931</a> (NCT00002555) and <a href="/clinicaltrials/NCT00002670">RTOG-9501</a> (NCT00002670) studies.[<a href="#cit/section_4.7">7</a>-<a href="#cit/section_4.10">10</a>][<a href="/Common/PopUps/popDefinition.aspx?id=810017
        end
        104096
        exact text
        NCT00002670
        start
        104085
      2. context exact
        based on a pooled analysis of the <a href="/clinicaltrials/NCT00002555">EORTC-22931</a> (NCT00002555) and <a href="/clinicaltrials/NCT00002670">RTOG-9501</a> (NCT00002670) studies.[<a href="#cit/section_4.7">7</a>-<a href="#cit/section_4.10">10</a>][<a href="/Common/PopUps/popDefinition.aspx?id=810017&amp;version=HealthProfessio
        end
        104124
        exact text
        NCT00002670
        start
        104113
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/2f62e0aa018c9f4893.html
      source file sha256
      31f0b7d3c9f8a622c00428041f6c731a10acf24c59277b3cd1a8fb560d317e44
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:21:46.804056+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      7c085a9f6221e622687066d2881d8d5d699cd85217f4b322d2597bd617a74997
      source title
      Oropharyngeal Cancer Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: May 14, 2025
        datetime
        2025-05-14T12:00:00Z
        display
        May 14, 2025
    2. release id
      ctgov-registry-7ad944f6deaf1f5cd6122126
      edge id
      nct-edge-cb6bbaa24a0e9ae2570e
      requested nct id
      NCT00002670
      primary nct id
      NCT00002670
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source file sha256
      39612e9b3ccb1c43b46f56e855558dcdf97c3dd977def4c90dd6e236c92cdbec
      payload sha256
      96a967dbe09a8c9b819107a27b78a0a2aaa8b6cfcb0e8ad442cda69a7818fe1b
      payload
      clinical indication matching status
      not_inferred
      end exclusive
      true
      id
      nct-edge-cb6bbaa24a0e9ae2570e
      link basis
      explicit_NCT_identifier_in_acquired_source
      nct id
      NCT00002670
      occurrences
      1. context exact
        h node, or positive margins, based on a pooled analysis of the <a href="/clinicaltrials/NCT00002555">EORTC-22931</a> [NCT00002555] and <a href="/clinicaltrials/NCT00002670">RTOG-9501</a> [NCT00002670] studies.[<a href="#cit/section_4.28">28</a>-<a href="#cit/section_4.31">31</a>][<a href="/Common/PopUps/popDefinition.aspx?id=8100
        end
        93989
        exact text
        NCT00002670
        start
        93978
      2. context exact
        based on a pooled analysis of the <a href="/clinicaltrials/NCT00002555">EORTC-22931</a> [NCT00002555] and <a href="/clinicaltrials/NCT00002670">RTOG-9501</a> [NCT00002670] studies.[<a href="#cit/section_4.28">28</a>-<a href="#cit/section_4.31">31</a>][<a href="/Common/PopUps/popDefinition.aspx?id=810017&amp;version=HealthProfess
        end
        94017
        exact text
        NCT00002670
        start
        94006
      offset unit
      unicode_code_points
      source file
      /tmp/cancer-full-research/nci/raw/cef8a92cf5abef45df.html
      source file sha256
      39612e9b3ccb1c43b46f56e855558dcdf97c3dd977def4c90dd6e236c92cdbec
      source json pointer
      Source null
      source kind
      nci_explicit_reference_or_link
      source record id
      Source null
      source retrieved at
      2026-09-09T23:21:45.568600+00:00
      source string basis
      UTF-8_text_with_universal_newline_translation
      source string sha256
      4b2cca4cd817d5312aba6dcd95eacc0edc1f9e1de24302b25dfc3698d3708a7a
      source title
      Laryngeal Cancer Treatment (PDQ®)–Health Professional Version
      source update dates
      1. context
        Updated: May 14, 2025
        datetime
        2025-05-14T12:00:00Z
        display
        May 14, 2025

    Preserved source evidence · Not medical advice